Review



epidermal growth factor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    MedChemExpress epidermal growth factor
    Epidermal Growth Factor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/EGF%2C+Human/pmc13091134-52-43-47
    Average 97 stars, based on 45 article reviews
    epidermal growth factor - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Salvianic Acid A Regulates Ferroptosis by Activating the Nrf2-GPX4 Pathway Through EGFR to Protect Myocardial Ischemia-Reperfusion Injury
    Article Snippet: .. Each group of mice was intervened with the corresponding drug before the operation, with Salvianic acid A (50 mg/kg) given via intraperitoneal injection for 14 consecutive days, and AG1478 (30 mg/kg, no. HY-13524, MCE, USA) and EGF (1 mg/kg, no. HY-P7067, MCE, USA) administered by intraperitoneal injection for 7 days. ..

    Single Cell:

    Article Title: A dual-pronged host-directed therapeutic targeting cyclophilin A and pathogenic interferon response abrogates virus-triggered pregnancy pathologies.
    Article Snippet: .. The resulting single-cell suspension was then isolated and plated in 5 μg/mL collagen Type IV (RD, #3410-010-01)-coated plates and maintained in a defined trophoblast stem cell culture medium composed of Advanced DMEM/F12 (Gibco, #12634-010), 0.2% FBS, 0.5% PS, 0.1 AR TI CL E IN P RE SS mM β-mercaptoethanol (Thermo Fisher Scientific, #21985023), 0.3% BSA (Sigma-Aldrich, #A9418), 1.5 μg/mL L-ascorbic acid (Wako, #013-12061), 1% ITS-X supplement (Thermo Fisher Scientific, #41400045), 50 ng/mL EGF (MedChemExpress, #HY-P7109), 0.5 μM A83-01 (MedChemExpress, #HY-10432), 2 μM CHIR99021 (Selleck, #S2924), 1 μM SB431542 (Wako, #031-24291), 0.8 mM VPA (Wako, #227-01071) and 5 μM Y27632 (Selleck, #S1049) following our previous protocol10, 79. ..

    Suspension:

    Article Title: A dual-pronged host-directed therapeutic targeting cyclophilin A and pathogenic interferon response abrogates virus-triggered pregnancy pathologies.
    Article Snippet: .. The resulting single-cell suspension was then isolated and plated in 5 μg/mL collagen Type IV (RD, #3410-010-01)-coated plates and maintained in a defined trophoblast stem cell culture medium composed of Advanced DMEM/F12 (Gibco, #12634-010), 0.2% FBS, 0.5% PS, 0.1 AR TI CL E IN P RE SS mM β-mercaptoethanol (Thermo Fisher Scientific, #21985023), 0.3% BSA (Sigma-Aldrich, #A9418), 1.5 μg/mL L-ascorbic acid (Wako, #013-12061), 1% ITS-X supplement (Thermo Fisher Scientific, #41400045), 50 ng/mL EGF (MedChemExpress, #HY-P7109), 0.5 μM A83-01 (MedChemExpress, #HY-10432), 2 μM CHIR99021 (Selleck, #S2924), 1 μM SB431542 (Wako, #031-24291), 0.8 mM VPA (Wako, #227-01071) and 5 μM Y27632 (Selleck, #S1049) following our previous protocol10, 79. ..

    Isolation:

    Article Title: A dual-pronged host-directed therapeutic targeting cyclophilin A and pathogenic interferon response abrogates virus-triggered pregnancy pathologies.
    Article Snippet: .. The resulting single-cell suspension was then isolated and plated in 5 μg/mL collagen Type IV (RD, #3410-010-01)-coated plates and maintained in a defined trophoblast stem cell culture medium composed of Advanced DMEM/F12 (Gibco, #12634-010), 0.2% FBS, 0.5% PS, 0.1 AR TI CL E IN P RE SS mM β-mercaptoethanol (Thermo Fisher Scientific, #21985023), 0.3% BSA (Sigma-Aldrich, #A9418), 1.5 μg/mL L-ascorbic acid (Wako, #013-12061), 1% ITS-X supplement (Thermo Fisher Scientific, #41400045), 50 ng/mL EGF (MedChemExpress, #HY-P7109), 0.5 μM A83-01 (MedChemExpress, #HY-10432), 2 μM CHIR99021 (Selleck, #S2924), 1 μM SB431542 (Wako, #031-24291), 0.8 mM VPA (Wako, #227-01071) and 5 μM Y27632 (Selleck, #S1049) following our previous protocol10, 79. ..

    Stem Cell Culture:

    Article Title: A dual-pronged host-directed therapeutic targeting cyclophilin A and pathogenic interferon response abrogates virus-triggered pregnancy pathologies.
    Article Snippet: .. The resulting single-cell suspension was then isolated and plated in 5 μg/mL collagen Type IV (RD, #3410-010-01)-coated plates and maintained in a defined trophoblast stem cell culture medium composed of Advanced DMEM/F12 (Gibco, #12634-010), 0.2% FBS, 0.5% PS, 0.1 AR TI CL E IN P RE SS mM β-mercaptoethanol (Thermo Fisher Scientific, #21985023), 0.3% BSA (Sigma-Aldrich, #A9418), 1.5 μg/mL L-ascorbic acid (Wako, #013-12061), 1% ITS-X supplement (Thermo Fisher Scientific, #41400045), 50 ng/mL EGF (MedChemExpress, #HY-P7109), 0.5 μM A83-01 (MedChemExpress, #HY-10432), 2 μM CHIR99021 (Selleck, #S2924), 1 μM SB431542 (Wako, #031-24291), 0.8 mM VPA (Wako, #227-01071) and 5 μM Y27632 (Selleck, #S1049) following our previous protocol10, 79. ..

    Tube Formation Assay:

    Article Title: The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment that Drives Tumor Radioresistance
    Article Snippet: D ow naded rom http://aacrjournals.orgarticle-pdf/doi/10.1158/0008-5472.C AN -25-3806/35/can-25-3806.pdf by gest on 15 M arch 2026 Radiotherapy resistance remains a major barrier to effective treatment of triple-negative breast cancer (TNBC), highlighting the need to identify mechanisms driving resistance.. Here, we identified SDC1 as a pivotal mediator of cancer-associated fibroblast (CAF)-induced radioresistance in breast cancer.. SDC1 bound the TIM barrel domain of the glycolytic enzyme ENO1, preventing FBXW7-mediated degradation and driving aerobic glycolysis and lactate accumulation.

    Cell Culture:

    Article Title: The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment that Drives Tumor Radioresistance
    Article Snippet: D ow naded rom http://aacrjournals.orgarticle-pdf/doi/10.1158/0008-5472.C AN -25-3806/35/can-25-3806.pdf by gest on 15 M arch 2026 Radiotherapy resistance remains a major barrier to effective treatment of triple-negative breast cancer (TNBC), highlighting the need to identify mechanisms driving resistance.. Here, we identified SDC1 as a pivotal mediator of cancer-associated fibroblast (CAF)-induced radioresistance in breast cancer.. SDC1 bound the TIM barrel domain of the glycolytic enzyme ENO1, preventing FBXW7-mediated degradation and driving aerobic glycolysis and lactate accumulation.

    other:

    Article Title: Electrospun collagen/hyaluronic acid dressing co-loaded with EGF and bFGF for enhanced diabetic wound healing
    Article Snippet: For growth factor loading, concentrated solutions of bFGF (HY-P5321, MCE) and EGF (HY-P7067, MCE) (50 μg mL −1 ) were added dropwise into the spinning solutions.

    Article Title: Targeting UBE2T by β-elemene inhibits prostate cancer stem cells and bone metastasis by blocking the TRIM28/pGSK3β/β-catenin signaling.
    Article Snippet: And then, fixed with 4% paraformaldehyde (P0099, Beyotime, Shanghai, China) and stained with Coomassie Blue (P0003S, Beyotime).



    Similar Products

    97
    MedChemExpress epidermal growth factor
    Epidermal Growth Factor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/EGF%2C+Human/pmc13091134-52-43-47
    Average 97 stars, based on 1 article reviews
    epidermal growth factor - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    99
    NSJ Bioreagents egfr antibody / egf receptor
    Egfr Antibody / Egf Receptor, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/EGFR+Antibody+%2F+EGF+Receptor/custom%40v5390%4042390288
    Average 99 stars, based on 1 article reviews
    egfr antibody / egf receptor - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    91
    Miltenyi Biotec mouse egf
    Mouse Egf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/Mouse+EGF%2C+research+grade/bio_rxiv__64898__2026__06__21__733630-124-10-12
    Average 91 stars, based on 1 article reviews
    mouse egf - by Bioz Stars, 2026-10
    91/100 stars
      Buy from Supplier

    99
    Bio-Techne corporation recombinant human egf protein, cf
    Recombinant Human Egf Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/Recombinant+Human+EGF+Protein%2C+CF/bio-techne+corporation___236-eg
    Average 99 stars, based on 1 article reviews
    recombinant human egf protein, cf - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    97
    MedChemExpress human egf
    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO <t>primary</t> <t>RTECs</t> treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following <t>EGF</t> stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.
    Human Egf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/EGF%2C+Human/pmc13440415-289-10-14
    Average 97 stars, based on 1 article reviews
    human egf - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology rp01030 recombinant human mature tgf beta 1 protein abclonal
    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO <t>primary</t> <t>RTECs</t> treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following <t>EGF</t> stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.
    Rp01030 Recombinant Human Mature Tgf Beta 1 Protein Abclonal, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/Recombinant+Human+EGF+Protein/pm42385712-276-90-97
    Average 94 stars, based on 1 article reviews
    rp01030 recombinant human mature tgf beta 1 protein abclonal - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology rp01042 recombinant human egf protein abclonal
    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO <t>primary</t> <t>RTECs</t> treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following <t>EGF</t> stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.
    Rp01042 Recombinant Human Egf Protein Abclonal, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/Recombinant+Human+FGF2+Protein/pm42385712-276-83-88
    Average 94 stars, based on 1 article reviews
    rp01042 recombinant human egf protein abclonal - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    RayBiotech inc human egf elisa kit
    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO <t>primary</t> <t>RTECs</t> treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following <t>EGF</t> stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.
    Human Egf Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/Human+EGF+ELISA/pm42354437-118-37-41
    Average 94 stars, based on 1 article reviews
    human egf elisa kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress egf
    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO <t>primary</t> <t>RTECs</t> treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following <t>EGF</t> stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.
    Egf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/EGF%2C+Mouse/pmc13289659-77-36-41
    Average 94 stars, based on 1 article reviews
    egf - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    97
    R&D Systems recombinant human egf
    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO <t>primary</t> <t>RTECs</t> treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following <t>EGF</t> stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.
    Recombinant Human Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egf/Recombinant+Human+EGF+Protein%2C+CF/pmc13091051-268-9-12
    Average 97 stars, based on 1 article reviews
    recombinant human egf - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO primary RTECs treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following EGF stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.

    Journal: Science Advances

    Article Title: Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase

    doi: 10.1126/sciadv.aeg2534

    Figure Lengend Snippet: ( A ) Representative LysoSensor Yellow/Blue DND-160 fluorescence images showing lysosomal pH in Ctrl and cKO primary RTECs treated with HG + PA, with quantification. ( B ) Calculated lysosomal pH values in indicated group, derived from the LysoSensor Yellow/Blue fluorescence ratio using a calibration curve. ( C ) Measurement of lysosomal phospholipase A 2 (PLA 2 ), phospholipase C (PLC), and phospholipase D (PLD) activities in indicated group. ( D ) Immunoblot analysis of EGFR degradation following EGF stimulation in Ctrl and cKO primary RTECs under HG + PA conditions, with quantification. ( E and F ) Immunoblotting of cathepsin B (CTSB) maturation (E) and LC3 and p62 (F) in HG + PA-treated Ctrl and cKO RTECs, with quantification. ( G ) Cell viability assay of HG + PA-treated Ctrl and cKO RTECs. ( H ) Calculated lysosomal pH measurement in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( I and J ) Measurement of lysosomal phospholipase A2 activities (I) and cathepsin activities (J) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. ( K and L ) Immunofluorescence staining of Nile Red (K) or LipidTOX (L) (red) together with LAMP1 (green) in HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1, with corresponding quantitative analyses. ( M ) Cell viability analysis of HG + PA-treated Ctrl and cKO RTECs following Forskolin treatment with or without BafA1. Data are presented as mean ± SEM. P values were determined by unpaired two-tailed Student’s t test for (A) to (G) and by one-way ANOVA followed by Tukey’s multiple-comparisons test for (H) to (M). Scale bar: 10 μm in (A), (K), and (L). n = 6 for (A), (K), and (L), n = 4 for (B) and (H), n = 3 for (C) to (F), (I), (J), and (M), n = 5 for (G). * P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant.

    Article Snippet: RTECs were serum-starved for 4 hours and stimulated with recombinant human EGF (100 ng/ml, MCE HY-P7109) for 0–120 min at 37°C.

    Techniques: Fluorescence, Derivative Assay, Western Blot, Viability Assay, Immunofluorescence, Staining, Two Tailed Test